Abstract: Techniques are for detecting presence of a problematic cellular entity in a target. In an example, using an analysis model, a fluorescence-based image is analyzed. The analysis model is trained using a number of reference fluorescence-based images for detecting the presence of problematic cellular entities in targets. Based on the analysis, a problematic cellular entity present in the target is detected. To perform the detection, the analysis model is trained to differentiate between the fluorescence in the fluorescence-based image emerging from the problematic cellular entity and the fluorescence in the fluorescence-based image emerging from regions other than the problematic cellular entity.

Abstract: A spectroscopic analyzer includes: an irradiator that irradiates a target measurement object with lights of a plurality of different wavelengths sequentially as a pre-irradiation, and, after the pre-irradiation, further irradiates the target measurement object with lights of a plurality of different wavelengths sequentially as a measurement-irradiation; a detector that, during the measurement-irradiation, detects reflected light, transmitted light, or a transmitted reflected light from the target measurement object at each of the plurality of different wavelengths of the measurement-irradiation and that outputs absorbance spectral data; a data analyzer that analyzes the absorbance spectral data; and a result display that displays analysis results related to components of the target measurement object.

Abstract: Indirect ELISAs to detect exposure to Felis catus gammaherpesvirus 1 (FcaGHV1) in domestic cats. These ELISAs detect feline serum antibodies to ORF52 and ORF38 of FcaGHV1. The ELISA assays are sensitive, specific, and adaptable for scale up use in high throughput diagnostics.

Abstract: Instrument control and data acquisition in advanced analytic systems that utilize optical pulses for sample analysis are described. Clocking signals for data acquisition, data processing, communication, and/or other data handling functionalities can be derived from an on-board pulsed optical source, such as a passively mode-locked laser. The derived clocking signals can operate in combination with one or more clocking signals from a stable oscillator, so that instrument operation and data handling can tolerate interruptions in operation of the pulsed optical source.

Abstract: The present relates to a measurement device (1) for the detection and/or measurement of particles in a fluid, the measurement device comprising a fluid source (11) for producing a flow of fluid (111) along a fluid flow path, a first laser source (12) positioned for emitting a first laser beam (120) of laser light in a measurement volume of the fluid flow path for light scattering; a scattered light detecting means (13) for detecting a presence of a particle in the fluid flow path through detection and measurement of laser beam light scattered on different angles by said particle, wherein it further comprises a second laser source (14) positioned for emitting a second laser beam (140) of laser light in said measurement volume of the fluid flow path for Raman and fluorescence excitation; a Raman and fluorescence detecting means (15) for detecting a Raman scattering signal emitted by the fluid and a Fluorescence signal emitted by said particle upon excitation by said second laser beam (140).

Abstract: A process for analysing epigenetically active regions of the genome.

Abstract: A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid. The chiral cationic lipid in one embodiment comprises a nonsteroidal cationic lipid having a structure represented by formula (I); wherein in R1 is a quaternary ammonium group, Y1 is a space chosen from a hydrocarbon chain, an ester, a ketone, and a peptide, C* is a chiral carbon, R2 and R3 are independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor-diesters, and combination thereof.

Abstract: A measurement method and a measurement reagent for cardiac troponin which enable accurate measurement of the amount of cardiac troponin contained in a sample irrespective of the type of the sample and the presence or absence of other components are disclosed. The measurement method for cardiac troponin, wherein cardiac troponin in a sample separated from a body is measured by an immunoassay, includes a pretreatment step of mixing the sample separated from a body with a pretreatment liquid containing one or both of a surfactant and an acidifier. The reagent for immunoassay of cardiac troponin includes a pretreatment liquid containing one or both of a surfactant and an acidifier.

Abstract: A method for providing variable function medical tests, comprising providing by a mobile device application a plurality of selectable medical test functions, receiving information from the mobile device application regarding test results from a test performed using a testing device, wherein the testing device includes an alignment target disposed on the testing device and a plurality of immunoassay test strips receiving at the server an image of the testing device from the mobile device application, determining by the server RGB values for a plurality of pixels of the image, normalizing by the server the RGB values into a single value, comparing by the server the single value to a control value stored on the server, and providing by the server a risk indicator, wherein the risk indicator indicates a likelihood of a presence of a medical condition.

Abstract: The invention provides novel compounds, reagents, systems, and methods for detecting a metabolite related to a NRTI in a biological sample, and use thereof in monitoring adherence to pre-exposure prophylaxis or anti-retroviral treatment. Such reagents comprise NRTI derivatives, analogs, NRTI derivatives conjugates, along with antibodies directed to same, which are useful for anti-body-based methods, such as a lateral flow immunoassay and other point of care devices.

Abstract: Methods are provided herein utilizing a stable cell line capable of efficient infection by African swine fever virus (ASFV) and also provides for the detection of the presence of virus in samples applied to the cells. Detection of the virus by means such as red blood cell rosetting is a surprising result given that the cell line is derived from African green monkeys. This cell line provides a marked improvement over the currently available testing strategies.

Abstract: Methods, systems, and devices for a multi-port storage-class memory interface are described. A memory controller of the storage-class memory subsystem may receive, from a host device, a request associated with host addresses. The memory controller may generate interleaved addresses with a low latency based on the host addresses. The interleaved addresses parallelize processing of the request utilizing a set of memory media ports. Each memory media port of the set of memory media port may operate independent of each other to obtain a desired aggregated data transfer rate and a memory capacity. The interleaved address may leave no gaps in memory space. The memory controller may control a wear-leveling operation to distribute access operations across one or more zones of the memory media port.

Abstract: The present invention relates to methods to detect an amount of DNA that originates from cells of a given type, where the sample comprising such DNA in admixture with DNA that does not originate from such cells. Such methods are based on differential methylation, at certain regions, of the DNA that originates from the given type of cells compared to the admixed DNA. Such methods have particular application in the detection, from a biological fluid from a pregnant female, of cell free DNA that originates from a foetus or the placenta of a foetus, or the detection, from a biological fluid from an individual, of cell free DNA that originates from cells of a tumour.

Abstract: A microfluidic routing device for routing objects of interest in a microfluidic flow includes a substrate; a first layer provided on the substrate, in which the first layer forms a bottom wall of a microfluidic channel. At least two holes through the first layer form respectively an inlet and an outlet for the microfluidic channel The microfluidic routing device further includes a second layer spaced away from the first layer, in which the second layer forms a top wall of the microfluidic channel. The second layer is configured to transmit an optical signal from the microfluidic channel. The microfluidic routing device includes an actuator for actuating the objects of interest in a sorting junction of the microfluidic channel.

Abstract: A measurement method and a measurement reagent for thyroglobulin, which enable measurement of a more accurate amount of thyroglobulin by a single test without being influenced by interference of anti-thyroglobulin antibody, are disclosed. The measurement method for thyroglobulin, wherein thyroglobulin in a sample separated from a body is measured by an immunoassay, includes a pretreatment step of mixing the sample separated from a body with a pretreatment liquid containing one or both of a surfactant and an acidifier. The reagent for immunoassay of thyroglobulin includes a pretreatment liquid containing one or both of a surfactant and an acidifier.

Abstract: A system that indicates the presence or absence of microorganisms in fluid food products. The system has a bottle for receiving sample to be tested. The bottle has a sensor that will monitor and detect changes in at least one sample parameter, but no additives that contain nutrients that support microbial growth. The bottle is placed in an incubator and the sensor in the bottle is monitored for changes. The incubator is programed so that, if the sensor detects that the value of the monitored parameter has reached a certain value, then the sample is determined to be positive for microbial growth.

Abstract: This disclosure provides a method for determining the likelihood of being at or beyond a certain rate and/or risk of visual field progression (VFP) of a user, that may include measuring ocular biomechanical properties (OBP) through a continuous-wear sensor placed on or implanted in the eye; recording the user's ocular biomechanical properties in the form of at least one OBP time series plot in a recorder, a processing step wherein at least one of a plurality of OBP parameters are extracted from the recorded OBP time series plot; a calculation step wherein the at least one of a plurality of OBP parameters are associated to VFP, and a determining step wherein one determines whether the visual field progression is at or beyond a certain VFP threshold and/or the probability that the said visual field progression is comprised within a specific range.

Abstract: Described herein are devices, systems, fluidic devices, kits, and methods for detection of target nucleic acids associated with diseases, cancers, genetic disorders, a genotype, a phenotype, or ancestral origin. The devices, systems, fluidic devices, kits, and methods may comprise reagents of a guide nucleic acid targeting a target nucleic acid, a programmable nuclease, and a single stranded detector nucleic acid with a detection moiety. The target nucleic acid of interest may be indicative of a disease, and the disease may be communicable diseases, or of a cancer or genetic disorder. The target nucleic acid of interest may be indicative of a genotype, a phenotype, or ancestral origin.

Abstract: The present invention relates to a method of quantifying the amount of Mock Virus Particles (MVP) removed from a solution as a result of processing that solution through a purification technique. This method involves the steps of adding MVP to a solution, processing the solution through a purification technique, quantifying the amount of MVP removed from the solution. The present invention also relates to a kit that can be used in conjunction with the method. This kit will comprise at least one stock solution of MVP and at least one quantification solution.

Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.

Abstract: Oligonucleotide analogues conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

Abstract: The disclosure provides methods and systems for designing and synthesizing probes to capture a representative sample of genomic variants of a target genome from a sample. The methods include providing a multiple sequence alignment (MSA), designing a plurality of representative subsequences, and optionally synthesizing a nucleic acid probe. The designing step can comprise designating a plurality of intervals in the MSA, shifting start positions for each MSA subset, clustering the aligned subsequences within each adjusted subset, and determining a representative sequence for each reduced MSA subset. The disclosure also encompasses methods of isolating a plurality of nucleic acid variants of a targeted genomic subregion from a sample using the disclosed probe design, as well as the probe compositions themselves.

Abstract: The present invention relates to CXCR6-transduced (a) T cell(s) such as (a) CD8+ T cell(s), (a) CD4+ T cell(s), (a) CD3+ T cell(s), (a) ?? T cell(s) or (a) natural killer (NK) T cell(s) for targeted tumor therapy, nucleic acid sequences, vectors capable of transducing such (a) T cell(s), (a) transduced T cell(s) carrying the nucleic acid sequences or vectors of the present invention, methods and kits comprising the nucleic acid sequences or vectors of the present invention. The invention also provides the use of said transduced T cell(s) in a method for the treatment of diseases characterized by CXCL16 overexpression as well as a pharmaceutical composition/medicament comprising (a) transduced T cell(s) expressing the CXCR6 for use in methods of treating diseases characterized by CXCL16 overexpression.

Abstract: Disclosed is a method of diagnosing multiple sclerosis (MS), wherein a blood sample from a patient is incubated with a DNA-replication associated (REP) protein. The present invention relates to a DNA-replication-associated (Rep) protein for use in the diagnosis of multiple sclerosis (MS), wherein (a) an increased amount of Rep protein or fragments thereof in the sample as compared to an amount in a control sample; or an increased amount of anti-Rep protein antibodies with antigen in a sample from a subject as compared to an amount in a control sample correlates with a diagnosis of MS, wherein the Rep protein is MSBI1 Rep or MSBI2 Rep.

Abstract: The present invention discloses a method and its variations for simultaneous detection of antibodies against two or more antigens of human immunodeficiency virus (HIV) and determination of approximate time (duration) post HIV infection, thereby confirming the infection, and determination of recency of an HIV infection. The number of individuals with recently infected HIV in a given period may be further used to estimate incidence of HIV in a population.

Abstract: A method and a device are for exchanging information regarding the clinical implications genomic variations. In an embodiment, the method includes receiving login-data of a user; evaluating the login-data received; establishing an encrypted data connection to the user after the evaluating indicates a positive evaluation of the login-data; saving, upon receiving a dataset in a context of a genomic variation, the dataset received in a memory, context-related with the genomic variation; and evaluating, upon a user request being received and connected with a search query for the genomic variation, a set of datasets from the memory, the datasets being context-related with the genomic variation and the set including the datasets that the user is authorized to receive, and sending the set of datasets to the user.

Abstract: The present disclose provides methods and systems for amplifying and quantifying nucleic acids and for detecting the presence or absence of a target in a sample. The methods and systems provided herein may utilize a device comprising a plurality of partitions separated from an external environment by a gas-permeable barrier. Certain methods disclosed herein involve subjecting nucleic acid molecules in the plurality of partitions to conditions sufficient to conduct nucleic acid amplification reactions. The nucleic acid molecules may be subjected to controlled heating in the plurality of partitions to generate data indicative of a melting point(s) of the nucleic acid molecules.

Abstract: A method for evaluating image quality is provided. The method may include: obtaining an image, the image including a plurality of elements, each element of the plurality of elements being a pixel or voxel, each element having a gray level; determining, based on a maximum gray level of the plurality of elements, one or more thresholds for segmenting the image; determining one or more sub-images of a region of interest by segmenting, based on the one or more thresholds, the image; and determining, based on the one or more sub-images of the region of interest, a quality index for the image.

Abstract: This disclosure provides an integrated and automated sample-to-answer system that, starting from a sample comprising biological material, generates a genetic profile in less than two hours. In certain embodiments, the biological material is DNA and the genetic profile involves determining alleles at one or a plurality of loci (e.g., genetic loci) of a subject, for example, an STR (short tandem repeat) profile, for example as used in the CODIS system. The system can perform several operations, including (a) extraction and isolation of nucleic acid; (b) amplification of nucleotide sequences at selected loci (e.g., genetic loci); and (c) detection and analysis of amplification product. These operations can be carried out in a system that comprises several integrated modules, including an analyte preparation module; a detection and analysis module and a control module.

Abstract: Disclosed are compositions related to synthetic PD-1 peptides, chimeric PD-1 peptides, anti-PD-1 antibodies and methods of treating cancers, autoimmune diseases, and Alzheimer's disease using said peptides or antibodies.

Abstract: The present disclosure relates to methods and compositions, e.g., kits, for quantitatively detecting an antibody of a subject to an infectious organism. In some embodiments, the present disclosure provides for methods and compositions, e.g., kits, for quantitatively detecting a human antibody to SARS-CoV-2 polypeptide or S (spike) polypeptide. Certain applications and uses of the present methods and compositions, e.g., kits, are also provided.

Abstract: The invention relates to polynucleotides comprising the sequence of a flavivirus preceded by a sequence encoding an N terminal part of a flavivirus Capsid protein, an immunogenic protein, or a part thereof comprising a an immunogenic peptide, and a 2A cleaving peptide, and to the virus encoded by such sequences. The invention further relates to the use of such polynucleotides and viruses as vaccines.

Abstract: Methods and assays for detecting natalizumab in a sample, natalizumab-peptide complexes in a sample, and point-of-care devices for detecting natalizumab in a sample are described herein.

Abstract: A test element for an assay includes: a cartridge having a housing which includes a priming pad capable of containing a liquid fluid, a wash port having an opening in the housing, and an opening for directly or indirectly applying a sample; and an assay device positioned within the cartridge in fluid communication with the wash port containing an analytical reagent.

Abstract: A portable nucleic acid extraction kit includes a portable nucleic acid extraction apparatus, at least one lysis buffer, at least one binding buffer, at least one washing buffer, at least one elution buffer, and at least three kit sample tubes. The portable nucleic acid extraction apparatus includes a handle, a rod, a tip, and may include a nucleic acid binding medium. The method of using the portable nucleic acid extraction apparatus includes, treating a biological sample having a nucleic acid, binding the nucleic acid in the treated biological sample to the tip of the portable nucleic acid extraction apparatus, incubating the tip of the portable nucleic acid extraction apparatus bound with the nucleic acid, washing the tip of the portable nucleic acid apparatus bound with the nucleic acid, eluting the bound nucleic acid, and analyzing the eluted nucleic acid.

Abstract: In some examples, a diagnostic device includes a reusable part to receive a container of a fluid, the reusable part reusable for a plurality of diagnostic tests. The diagnostic device further includes a disposable part detachably attached to the reusable part and comprising a sample collector to collect a target sample of a living being. The diagnostic device further includes a tester comprising a fluid channel to transport the fluid to combine the fluid and the target sample to form a fluid combination, and to use the fluid combination to diagnose a condition of the target sample.

Abstract: The invention relates to antisense molecules and methods for modulating splicing of polyomavirus T antigen pre-mRNA. In one aspect the invention relates to an antisense oligonucleotide 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length which comprises a sequence that is the reverse complement of a contiguous stretch of at least 12 nucleobases of a polyomavirus T-antigen pre-mRNA and which antisense oligonucleotide can modulate splicing of said T-antigen pre-mRNA in a cell.

Abstract: A method of automatically sequencing or basecalling one or more DNA (deoxyribonucleic acid) molecules of a biological sample is described. The method comprises using a capillary electrophoresis genetic analyzer to measure the biological sample to obtain at least one input trace comprising digital data corresponding to fluorescence values for a plurality of scans. Scan labelling probabilities for the plurality of scans are generated using a trained artificial neural network comprising a plurality of layers including convolutional layers. A basecall sequence comprising a plurality of basecalls for the one or more DNA molecules based on the scan labelling probabilities for the plurality of scans is determined.

Abstract: Methods, systems, and apparatus, including computer programs encoded on computer-storage media, for sea lice mitigation. In some implementations, a method includes obtaining multiple observations of a population of reference fish across a period of time, generating, from the multiple observations, a record for each reference fish that indicates an extent of sea lice infestation for the reference fish across the period of time, training, based on the records, a model that determines a predicted health indicator for a fish, obtaining an image of a sample fish that is not in the population of reference fish, determining, based on the image of the sample fish and with the model, a predicted health indicator for the sample fish, and selectively initiating sea lice mitigation based on the predicted health indicator.

Abstract: The present invention discloses a method for detecting Influenza A virus and Influenza B virus in a suspected sample by detecting the matrix gene and the non-structural gene, respectively. The signals can be detected by a fluorescent detection system.

Abstract: Provided herein are methods to characterize preparations of recombinant viral particles using analytical ultracentrifugation. Recombinant viral particles include recombinant adeno-associated viral particles, recombinant adenoviral particles, recombinant lentiviral particles and recombinant herpes simplex virus particles. Variant species of recombinant viral particles including empty capsids and recombinant viral particles with variant genomes (e.g., truncated genomes, aggregates, recombinants) can be identified and quantitated. The methods can be used to characterize preparations of recombinant viral particles regardless of the sequence of the recombinant viral genome or the serotype of the recombinant viral capsid.

Abstract: Provided herein are compositions and methods for sorting and/or identifying live cells. The compositions and methods provide for staining of live cells with aptamer so particular cells can be identified within or sorted from a heterogeneous population of live cells and subsequent reversal of the staining to prepare sorted and/or identified cells in their native state.

Abstract: An analyte-sensitive substance is provided that has an optical property related to the concentration of an analyte. The analyte-sensitive substance includes an ionophore or other substance configured to provide a local pH, within the analyte-sensitive substance, that is related to the concentration of the analyte proximate the analyte-sensitive substance. The analyte-sensitive substance further includes a pH-sensitive fluorophore that increases or decreases its intrinsic fluorescence intensity with the local pH across a specified range of pH values. The analyte-sensitive substance further includes a pH-sensitive quencher configured to increase the slope of the change of fluorescence intensity of the pH-sensitive fluorophore across the specified range of pH values. The analyte-sensitive substance may further include an ionic additive configured to adjust the local pH such that the specified range of pH values corresponds to a range of analyte concentration values of interest.

Abstract: Provided is a method of producing reassortant influenza virus containing an antigenic protein of the first influenza virus strain, the method including the following steps: 1) a step of irradiating the first influenza virus strain with ultraviolet light in such an irradiation dose that the first influenza virus strain has initial infection ability and loses or is reduced in virus growth potential; 2) a step of infecting a host with the first influenza virus strain and the second influenza virus strain; 3) a step of culturing the host infected with the first influenza virus strain and the second influenza virus strain, to obtain culture product; 4) a step of inactivating influenza virus strain having an antigenic protein of the second influenza virus strain in the culture product obtained in the step 3); and 5) a step of collecting reassortant influenza virus after the step 4).

Abstract: Embodiments relate to predicting height information for an object. First distance data is determined at a first time when an object is at a first position that is only partially within the field-of-view. Second distance data is determined at a second, later time when the object is at a second, different position that is only partially within the field-of-view. A distance measurement model that models a physical parameter of the object within the field-of-view is determined for the object based on the first and second distance data. Third distance data indicative of an estimated distance to the object prior to the object being entirely within the field-of-view of the distance sensing device is determined based on the first distance data, the second distance data, and the distance measurement model. Data indicative of a height of the object is determined based on the third distance data.

Abstract: The system and method for biometric safe blood donor certification and geo-location system provides a safe blood donor biometric certification and geolocation tracking system that is an efficient, accurate, and portable device to acquire biometric data to authenticate identity of an individual and link the biometric identity to the blood test samples and results. This technology can unequivocally identify the person with their blood profile. The technology can track location of potential donor individuals with geo-location Global Positioning Satellite sensors and alert these individuals when a nearby patient requests their blood type. All eligible blood donors can be alerted about the opportunity to respond and accept the invitation for blood donation. Those who donate blood are removed from the eligibility list until they can safely donate again. This system eliminates the need for complex equipment and facilities to store donated blood for extended periods and eliminates waste of unused blood.

Abstract: Nucleic acid reagents and corresponding methods of using the same for monitoring and evaluating nucleic acid extraction and amplification reactions.

Abstract: The present invention relates to methods of detecting an infection in a subject based on the relative abundance of target molecules indicative of the expression of at least the gene pair DUSP1 and IFI27. In particular, the invention relates to a method of distinguishing between a bacterial infection or a non-bacterial infection in a subject, especially between bacterial and non-bacterial lower respiratory system infections using the gene pair. Further, the invention provides the medical use of therapeutic agents in the treatment of a bacterial or non-bacterial infection in a subject identified as having such an infection through use of a method of the invention, and monitoring the therapeutic effectiveness.

Abstract: Disclosed herein are methods for isolating target cells from blood, involving mixing in an open container an undiluted blood sample having a volume of 10 ml or less, and binding agents, wherein each binding agent comprises (A) a primary binding agent comprising an agent capable of binding to at least one cellular epitope on target cells in the undiluted blood sample, (B) a first linker bound to the primary binding agent, to generate binding agent-attached target cells in the undiluted blood sample; contacting the binding agent-attached target cells in the undiluted blood sample with a plurality of buoyant reagents that include a second linker capable of binding to the first linker to generate an undiluted buoyant reagent-attached target cell mixture; diluting the undiluted buoyant reagent-attached target cell mixture by at least 20% to produce a diluted buoyant reagent-attached target cell mixture; applying a vectorial force, such as centrifugal force, to the diluted buoyant reagent-attached target cell mixtu

Abstract: The present disclosure relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present disclosure provides a composition comprising a nucleic acid molecule encoding a HCV antigen, an HCV antigen, an adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleic acid molecule encoding a HCV antigen, an HCV antigen, an adjuvant, or a combination thereof.